MetaCap

Cytek Biosciences Inc. (CTKB)

NASDAQ: CTKBIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

6.12-0.20 (-3.16%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CTKB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$800.40M
EPS (TTM)
-$0.63
52-week range
3.31 – 6.39
Day range
5.99 – 6.39
Volume / Avg
1.77M / 1.31M
Beta
—

52-week range

$3.31$6.39

CTKB stock today

Shares of Cytek Biosciences (CTKB) finished lower on Nov 20 at $6.12, a drop of 3.16% or $0.20 per share, versus the S&P 500's 3.70% decline. At this level, CTKB sits near the top of its 52-week range of $3.31 to $6.39: 4.2% below the high, set on Nov 20, 2026 and 84.9% above the low. CTKB is up 21.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 4.1%.

Cytek Biosciences has posted a net loss over the last twelve months (EPS of -$0.63), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cytek Biosciences

Company profile

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Dr. Wenbin Jiang Ph.D.
Headquarters
Fremont, CA
Employees
703
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Cytek Biosciences generated $201.5 million in revenue, up 0.5% from fiscal 2024, its 5th consecutive year of revenue growth. Cytek Biosciences reported a net loss of $66.5 million, compared with a loss of $6.0 million a year earlier. Gross margin was 51.8% (down from 55.4%) and operating margin -20.0%.

Cytek Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$201.49M$200.45M$193.01M$2.96M$2.18M
Growth+0.52%+3.85%+6414.17%+35.86%+207.18%
Net income$-66.54M$-6.02M$-12.15M$2.48M$3.03M
EPS (diluted)$-0.52$-0.05$-0.09$0.02$0.00

Analyst forecast

Forecast

Consensus (3 analysts)

buy

Avg. price target

$6.50+6.21%

  • Strong buy 1
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $7.50

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.05 vs $-0.08
Surprise
+37.50%

CTKB news

All CTKB news

Cytek Biosciences peers

Industrials sector
CTKB peer companies
CompanyPrice% ChgMarket capCompare
PACBPacific Biosciences of California Inc.1.63-7.39%$508.95Mvs CTKB
NAUTNautilus Biotechnology Inc.2.12-2.30%$270.03Mvs CTKB
LABStandard BioTools Inc.0.631+2.82%$249.11Mvs CTKB
QTRXQuanterix Corporation1.96-3.45%$93.06Mvs CTKB
SEERSeer Inc. Class A1.36-1.81%$75.91Mvs CTKB
HBIOHarvard Bioscience Inc.8.66-0.23%$39.60Mvs CTKB
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs CTKB
PRPOPrecipio Inc.17.35-6.17%$31.11Mvs CTKB

Indexes, lists and sector

Cytek Biosciences stock FAQ

What is Cytek Biosciences's stock price today?

CTKB last traded at $6.12 as of Nov 20, 4:00 PM EST, down 3.16% on the day. Prices are delayed at least 15 minutes.

Who is Cytek Biosciences's CEO?

Dr. Wenbin Jiang Ph.D. is the chief executive officer of Cytek Biosciences Inc., which has about 703 employees.

What is the CTKB 52-week high?

The 52-week high for CTKB is $6.39 and the 52-week low is $3.31. The stock is currently 4.2% below its high.

Compare CTKB